Company / PP&E (Net)
Arcus Biosciences, Inc. PP&E (Net) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$40.0M
FY2025
5-year range
$32.0M / $51.0M
FY2021-FY2025
Trend
-14.9%
vs FY2024
Sector context
#68 of 193
Health Care
What the data says
At $40M, Arcus Biosciences, Inc.'s pp&e (net) ranks #68 of 193 in the Health Care sector. Declined from $51M to $40M over the past 2 years.
Based on SEC 10-K filings.
$40M in FY2025 with a 5-year CAGR of +29.9%.
Declined from $51M to $40M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +4.6%
- 5-Year CAGR
- +29.9%
- 10-Year CAGR
- -
Sector benchmark
#68 of 193 in Health CareTop 35% of 193This company $40.0M Sector average $777.6M
▼
-94.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +29.9%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 14.9% year-over-year.
- Ranks #68 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -0.93 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $40.0M | -14.9% |
| FY2024 | $47.0M | -7.8% |
| FY2023 | $51.0M | +45.7% |
| FY2022 | $35.0M | +9.4% |
| FY2021 | $32.0M | +196.1% |
| FY2020 | $10.8M | +15.8% |
| FY2019 | $9.3M | -16.0% |
| FY2018 | $11.1M | -1.1% |
| FY2017 | $11.2M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026